High-dose inhaled albuterol in severe chronic airflow limitation.

Author: BrittonJ R, CooksonJ B, EbdenP, TattersfieldA E, VathenenA S, WharradH J

Paper Details 
Original Abstract of the Article :
Higher doses of inhaled albuterol have been shown to cause slightly more bronchodilatation than standard doses from a metered-dose inhaler in patients with severe chronic airflow limitation. Higher doses, however, carry an increased risk of side effects, and the optimum dose balancing benefit and ad...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1164/ajrccm/138.4.850

データ提供:米国国立医学図書館(NLM)

High-Dose Inhaled Albuterol for Chronic Airflow Limitation

Navigating the complexities of pulmonary medicine is like exploring a vast desert, where every breath is a challenge. This study, like a seasoned explorer seeking the optimal route, investigated the effects of high-dose inhaled albuterol in patients with severe chronic airflow limitation. The researchers carefully measured the bronchodilation and adverse effects associated with increasing doses of albuterol, seeking to find the delicate balance between benefit and risk.

Finding the Right Dosage: A Balancing Act

The study revealed a dose-dependent increase in bronchodilation with high doses of inhaled albuterol, but also noted a corresponding increase in side effects. This finding highlights the importance of carefully considering the individual needs of each patient and finding the optimal dose that maximizes benefit while minimizing risk. Like a desert traveler seeking a balance between hydration and carrying capacity, healthcare providers must carefully weigh the benefits and risks of each treatment strategy.

Navigating the Desert of Chronic Airflow Limitation

The study provides valuable insights into the use of high-dose inhaled albuterol in patients with chronic airflow limitation. It emphasizes the need for careful monitoring and individualization of treatment to ensure the best possible outcomes for each patient. Just as a skilled navigator guides a caravan through a treacherous desert, healthcare providers must carefully adapt treatment strategies to meet the unique needs of their patients.

Dr.Camel's Conclusion

This study highlights the need for careful consideration of the benefits and risks of high-dose inhaled albuterol in patients with severe chronic airflow limitation. It emphasizes the importance of individualizing treatment strategies to optimize outcomes for each patient.

Date :
  1. Date Completed 1989-01-26
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

2462383

DOI: Digital Object Identifier

10.1164/ajrccm/138.4.850

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.